drugset

drugset / Trial / NCT00083694

Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia

NCT00083694 ↗

Phase 2 Completed 25 enrolled University of Arkansas Celgene Corporation · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Thalidomide in patients with leukemia.

Timeline

Start: 1998-08
Primary completion: —
Completion: 2005-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Thalidomide	Other / unclassified	—	—

Indications